Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Roflumilast 500 μg Tablets Once Daily at Acute COPD Exacerbations Treated With Standard Therapy of Oral Steroids and Antibiotics. A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial

NCT01473758 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01473758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01473758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Roflumilast 500 μg Tablets Once Daily at Acute COPD Exacerbations Treated With Standard Therapy of Oral Steroids and Antibiotics. A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
February 29, 2012
Completion date
March 31, 2014
Enrollment
81 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease with (acute) exacerbation